Citrin缺陷导致的新生儿肝内胆汁淤积症临床和SLC25A13基因突变的研究

目的 探讨citrin缺陷导致的新生儿肝内胆汁淤积症(neonatalintrahepatic cholestasis caused by citrin deficiency,NICCD)患儿的临床表现、实验室检查特点、SLC25A13基因突变情况及预后.方法 对26例NICCD患儿进行常规实验室检查、血氨基酸谱和酰基肉碱谱、尿有机酸和SLC25A13基因分析,并随访2年.结果 NICCD患儿出生体重偏低,平均黄疸出现年龄29 d.实验室检查改变包括肝功能异常、高胆红素血症、低蛋白血症、甲胎蛋白升高、凝血酶原时间延长及低血糖、高氨血症.串联质谱分析发现多数患儿有瓜氨酸等氨基酸特异性升高.尿气相色谱质谱有机酸分析有尿4-羟基苯乳酸和4-羟基苯丙酮酸升高.SLC25A13基因分析共发现12种致病突变,其中G386V,R467X,K453R,1192-1193delT为新突变.26例患儿的突变总检出率84.6%,851del4、1638ins23及IVS6+5G＞A为热点突变,突变率分别占总突变的40.9%、20.5%和11.4%.26例NICCD患儿中5例(19.2%)预后不良,4例死亡,1例接受肝移植.NICCD患儿的基因型与临床表型相关性不明显.结论 851del4、1638ins23及IVS6+5G＞A突变为中国人SLC25A13基因的热点突变,部分NICCD患儿可能预后不良.     

Citrin缺陷导致的新生儿肝内胆汁淤积症临床和SLC25A13基因突变的研究

Objectives To investigate the clinical and laboratory features of neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) and to characterize the molecular basis and prognosis of this disease. Methods Twenty-six patients with NICCD were collected because of idiopathic intrahepatic cholestasis and jaundice. The diagnosis was made by routine laboratory data collection, tandem mass spectrometry (MS-MS) and gas chromatography mass spectrometry (GC-MS) analyses. SLC25A13 gene mutation was analyzed by using polymerase chain reaction (PCR), direct DNA sequencing and restriction fragment length polymorphism analyses. The patients were followed up for nearly 2 years. Results The NICCD patients showed low birth weight and the average onset of jaundice was 29 days. Laboratory data showed liver dysfunction, hyperbilirubinemia, hypoproteinemia, high levels of α-fetoprotein, prolonged prothrombin time, hypoglycemia and hyperammonemia. MS-MS analysis of the blood samples revealed specific elevation of citrulline, methionine, threonine, tyrosine and elevation of free carnitine, short-chain and long-chain acylcarnitines. GC-MS analysis of the urine samples showed elevated 4-hydroxyl phenyllactic acid and 4-hydroxyi phenylpyruvic acid. Twelve different mutations were identified, including 4 novel mutations, i. e. , G386V, R467X, K453R and 1192-1193delT. Forty-four mutated alleles were identified in the 52 alleles (84.6%). Among them, 851del4, 1638ins23 and IVS6+5G＞A mutations were the most frequent mutations, accounting for 40.9%, 20.5% and 11.4% of the total alleles examined respectively.Five of the 26 patients have not been recovered, including 4died and 1 accepted liver transplantation. No obvious relationship was found between the genotype and phenotype in NICCD. Conclusion The 851del4,1638ins23 and IVS6+5G＞A mutations are the hot-spot mutations in Chinese NICCD patients. Some NICCD patients have poor prognosis.     

Citrin缺陷导致的新生儿肝内胆汁淤积症临床和SLC25A13基因突变的研究

Objectives To investigate the clinical and laboratory features of neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) and to characterize the molecular basis and prognosis of this disease. Methods Twenty-six patients with NICCD were collected because of idiopathic intrahepatic cholestasis and jaundice. The diagnosis was made by routine laboratory data collection, tandem mass spectrometry (MS-MS) and gas chromatography mass spectrometry (GC-MS) analyses. SLC25A13 gene mutation was analyzed by using polymerase chain reaction (PCR), direct DNA sequencing and restriction fragment length polymorphism analyses. The patients were followed up for nearly 2 years. Results The NICCD patients showed low birth weight and the average onset of jaundice was 29 days. Laboratory data showed liver dysfunction, hyperbilirubinemia, hypoproteinemia, high levels of α-fetoprotein, prolonged prothrombin time, hypoglycemia and hyperammonemia. MS-MS analysis of the blood samples revealed specific elevation of citrulline, methionine, threonine, tyrosine and elevation of free carnitine, short-chain and long-chain acylcarnitines. GC-MS analysis of the urine samples showed elevated 4-hydroxyl phenyllactic acid and 4-hydroxyi phenylpyruvic acid. Twelve different mutations were identified, including 4 novel mutations, i. e. , G386V, R467X, K453R and 1192-1193delT. Forty-four mutated alleles were identified in the 52 alleles (84.6%). Among them, 851del4, 1638ins23 and IVS6+5G＞A mutations were the most frequent mutations, accounting for 40.9%, 20.5% and 11.4% of the total alleles examined respectively.Five of the 26 patients have not been recovered, including 4died and 1 accepted liver transplantation. No obvious relationship was found between the genotype and phenotype in NICCD. Conclusion The 851del4,1638ins23 and IVS6+5G＞A mutations are the hot-spot mutations in Chinese NICCD patients. Some NICCD patients have poor prognosis.     

Citrin缺陷导致的新生儿肝内胆汁淤积症患儿SLC25A13基因突变与生化指标的相关性研究*

 目的：分析citrin缺陷导致的新生儿肝内胆汁淤积症(NICCD)患儿SLC25A13基因突变及生化改变特点,并探讨两者相关性。方法：2013年3月至2013年10月在暨南大学附属第一医院以胆汁淤积性肝病就诊的婴儿59例,其中经SLC25A13基因分析确诊的NICCD患儿36例为病例组,排除NICCD且未发现明确病因的23例特发性新生儿胆汁淤积症(INC)患儿为对照组。抽取静脉血提取DNA进行SLC25A13突变检测,并分析所有研究对象的血糖、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、γ-谷氨酰转移酶（GGT）、碱性磷酸酶（ALP）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）等数据资料。结果：NICCD组ALT及LDL-C水平低于对照组。检出SLC25A13基因突变10种,其中851del4、IVS16ins3kb、IVS6+5G>A和1638ins23 突变占全部突变数量的82%。不同性别及年龄段的NICCD患儿其SLC25A13基因突变分布未见不同。SLC25A13基因突变与患儿的血糖、ALT、AST、ALP、TG及HDL-C水平无关联,而与GTT的水平有关联。结论：低LDL-C血症可能是NICCD患儿血脂紊乱的特点。NICCD患儿SLC25A13基因的高频突变类型为851del4、IVS16ins3kb、IVS6+5G>A和1638ins23。本文NICCD患儿的SLC25A13突变分布与GGT水平之间存在相关性,但这一发现的意义有待深入研究。     

Citrin缺陷致新生儿肝内胆汁淤积症患儿生化改变研究

目的探讨citrin缺陷致新生儿肝内胆汁淤积症（NICCD）患儿生化改变特征。方法对经基因学确诊且平均月龄为3个月的26例NICCD患儿进行常规生化检查、气相色谱质谱检查及串联质谱检查并分析。结果 NICCD患儿血清总胆红素、直接胆红素、谷草转氨酶、谷丙转氨酶及乳酸水平升高均占100%,血氨及甲胎蛋白水平升高均占95.2%,胆汁酸水平升高占90.0%,低蛋白水平占84.0%,血脂水平升高占50%。半乳糖增高占78.3%,4-羟基苯乳酸增高占52.2%。C14增高占84.7%,C16增高占71.4%,瓜氨酸增高占66.7%。结论 NICCD患儿存在糖,氨基酸及脂肪酸代谢异常,以半乳糖、瓜氨酸及长链酰基肉碱增高明显。     

婴儿肝内胆汁淤积症SLC25A13基因突变分析

目的探讨SLC25A13基因突变在中国婴儿肝内胆汁淤积症患儿中的检出率,初步了解突变患儿血生化及氨基酸谱特征,肝脏活组织病理变化。方法2003年12月至2006年12月就诊于复旦大学附属儿科医院的婴儿肝内胆汁淤积症患儿,满足本研究入选条件者共115例进行了血氨基酸质谱分析,伴血浆瓜氨酸明显升高的患儿进行SLC25A13基因全部外显子及邻近序列测序,不伴血浆瓜氨酸明显升高的患儿进行SLC25A13基因常见突变851del4（突变Ⅰ）及突变1638ins23（突变Ⅲ）筛查,突变851del4采用实时荧光定量PCR双标记探针法检测,突变1638ins23采用PCR产物直接电泳法检测,对仅检出单个位点突变的筛查对象,继续进行其余已报道的10种突变位点检测。检测结果仍为单个杂合突变的对象进行SLC25A13基因所有外显子区及其邻近序列分析。对确诊突变患儿的临床表现、血生化及血氨基酸特征等进行分析。结果5例伴血瓜氨酸明显升高的患儿共检出突变4例,其中纯合突变851del4/851del41例,复合杂合突变851del4/1638ins231例,杂合突变851del42例;110例不伴血浆瓜氨酸明显升高患儿共检出突变6例,其中纯合突变851del4/851del41例,复合杂合突变851del4/1638ins231例,杂合突变851del44例。115例婴儿肝内胆汁淤积症患儿共检出SLC25A13基因突变10例,占8.7%。突变患儿血生化改变包括胆红素、γ-谷氨酰转移酶以及碱性磷酸酶等明显升高,AST升高较ALT明显。血串联质谱发现5例突变患儿有特征性氨基酸瓜氨酸、苏氨酸及蛋氨酸升高,另5例突变患儿并无血氨基酸改变。10例患儿中有7例行肝脏活组织病理学检查,4例有显著的脂肪变性。结论SLC25A13基因突变是中国婴儿肝内胆汁淤积症的重要原因之一。肝脏活组织病理、血生化及氨基酸谱等检查对诊断SLC25A13基因突变患儿有重要意义,但最终仍需通过基因检测确诊。     

五例新生儿肝内胆汁淤积症患儿基因的突变分析CSCD

目的明确5例新生儿肝内胆汁淤积症患儿的分子机制。方法应用新一代测序技术对患儿的SLC25A13基因进行外显子捕获检测,对突变位点进行Sanger测序验证。用PolyPhen-2软件对新突变的致病性进行分析。结果 5例患儿均携带SLC25A13基因的复合突变,共发现8个突变位点,其中2个既往未见报道(c.1357A>G和c.1663dup23)。5例患儿的父母均为突变携带者。结论 SLC25A13基因的突变可能是5例患儿的发病原因,所携带的突变以851del4和1638-1660dup为主。新发现的c.1357A>G和c.1663dup23突变丰富了SLC25A13基因的突变谱。     

16例Citrin蛋白缺陷所致的婴儿肝内胆汁淤积症的 SLC25A13基因变异分析

目的:探讨16例Citrin蛋白缺陷所致的婴儿肝内胆汁淤积症(neonatal intrahepatic cholestasis caused by citrin deficiency,NICCD) SLC25A13基因的变异特点。 方法:应用高通量测序法对目标基因的编码外显子和侧翼区域进行捕获...     

16例Citrin蛋白缺陷所致的婴儿肝内胆汁淤积症的SLC25A13基因变异分析CSCD

目的探讨16例Citrin蛋白缺陷所致的婴儿肝内胆汁淤积症(neonatal intrahepatic cholestasis caused by citrin deficiency,NICCD)SLC25A13基因的变异特点。方法应用高通量测序法对目标基因的编码外显子和侧翼区域进行捕获,对变异位点进行Sanger测序验证和致病性分析。结果在16例NICCD患儿中,共发现致病变异15种,其中6种既往未见报道,包括IVS14-9A>G、c.1640G>A、c.762 T>A、c.736delG、c.1098delT、c.851G>A。结论通过高通量测序发现6种新变异,丰富了SLC25A13基因的变异谱,为患儿家系的遗传咨询和产前诊断提供了依据。     

高分辨率熔解曲线技术在筛查琥珀酸半醛脱氢酶缺陷症致病基因突变中的应用

目的对4例琥珀酸半醛脱氢酶缺陷症(SSADHD)患儿家系进行基因突变分析,在明确突变的基础上建立针对醛脱氢酶5家族成员A1基因(ALDH5A1)中常见致病基因突变位点c.1529C> T(p.S510F)的高分辨率熔解(HRM)曲线快速筛查方法。方法先证者4例SSADHD患儿年龄(5.3±2.2)个月,其中男性3例,女性1例。商品化试剂盒提取4例先证者及其亲属外周血基因组DNA;采用一代测序技术对患者家系的ALDH5A1进行基因突变分析;应用HRM曲线技术随机筛查80例患儿ALDH5A1上c.1529C> T位点突变。结果先证者均有致病基因突变c.1529C> T位点,其中2例为该位点纯合突变,2例杂合携带并伴有其他致病位点的杂合突变。先证者及其家属的HRM分析结果与测序结果一致。随机检测的80例患儿,年龄为(7.5±3.9)岁,其中男性48例,女性32例,均不携带该基因突变。结论推测c.1529C> T位点突变可能是津冀地区SSADHD患儿中ALDH5A1的常见致病基因突变位点,但其在人群中携带频率很低;利用HRM曲线技术可实现对该位点的快速筛查。     

Neonatal intrahepatic cholestasis caused by citrin deficiency in Korean infants

Citrin is a liver-type mitochondrial aspartate-glutamate carrier encoded by the SLC25A13 gene, and its deficiency causes adult-onset type II citrullinemia and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). Here, the authors investigated clinical findings in Korean infants with NICCD and performed mutation analysis on the SLC25A13 gene. Of 47 patients with neonatal cholestasis, three infants had multiple aminoacidemia (involving citrulline, methionine, and arginine) and galactosemia, and thus were diagnosed as having NICCD. Two of these three showed failure to thrive. The laboratory findings showed hypoproteinemia and hyperammonemia, and liver biopsies revealed micro-macrovesicular fatty liver and cholestasis. The three patients each harbored compound heterozygous 1,638-1,660 dup/ S225X mutation, compound heterozygous 851del4/S225X mutation, and heterozygous 1,638-1,660 dup mutation, respectively. With nutritional manipulation, liver functions were normalized and catch-up growth was achieved. NICCD should be considered in the differential diagnosis of cholestatic jaundice in Korean infants.     

Screening of SLC25A13 mutations in early and late onset patients with citrin deficiency and in the Japanese population: Identification of two novel mutations and establishment of multiple DNA diagnosis methods for nine mutations

We have recently identified SLC25A13 on chromosome 7q21.3 as the gene responsible for adult‐onset type II citrullinemia (CTLN2) and found seven mutations in the SLC25A13 gene of CTLN2 patients. Most recently, the SLC25A13 mutations have been detected in neonatal/infantile patients with a type of neonatal hepatitis associated with cholestasis (NICCD). In the present study, we identified a novel mutation, E601X, in the SLC25A13 gene and established multiple DNA diagnosis methods for eight mutations by using a genetic analyzer with GeneScan and the single primer extension procedure (SNaPshot). An additional novel missense mutation (variation), E601K, was detected by SNaPshot analysis and was indistinguishable from the mutation E601X detected by the PCR/RFLP method. Multiple DNA diagnoses for the nine mutations revealed that 100 (male/female: 70/30) out of 115 CTLN2 and 38 (14/24) out of 45 NICCD patients tested were homozygotes or compound heterozygotes. The frequency of homozygotes carrying SLC25A13 mutations in both alleles is estimated to be minimally 1 in 21,000 from carrier detection (18 in 1,315 individuals tested) in the Japanese population. The differences in the gender ratio and in mutation types between CTLN2 and NICCD patients are significant. It is, however, unknown whether all homozygotes with mutated SLC25A13 in both alleles suffer from NICCD, CTLN2, both, or neither. Hum Mutat 19:122–130, 2002. © 2002 Wiley‐Liss, Inc.